Application of serologanic acid in preparation of products for promoting bone growth or treating bone diseases

The combination of oxidized equine gnostic genolic acid and cannabinoid receptor 2 discovered by osteoblast membrane chromatography solves the problems of adverse reactions and lipophilic properties of existing osteoporosis treatment drugs, significantly promotes bone growth and treats bone diseases, and provides New drug or food candidates for preventing and treating osteoporosis.

CN118924776APending Publication Date: 2024-11-12ZHEJIANG CHINESE MEDICAL UNIVERSITY
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410992676.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-23
Publication Date
2024-11-12

AI Technical Summary

Technical Problem

There are adverse reactions to existing osteoporosis treatment drugs, and most cannabinoid receptor 2 (CB2) ligands are not suitable for clinical application due to their lipophilic properties, making it difficult to effectively promote bone growth or treat bone diseases.

Method used

Hydrophilic compounds found by osteoblast membrane chromatography have been oxidized by oxidation of equinoxine genolic acid, which binds to cannabinoid receptor 2 (CNR2), promotes bone growth and treats bone diseases, and have good molecular docking and binding activity and upregulation of expression levels. .

Benefits of technology

The oxidation of oxidized marcopene significantly promotes the proliferation, differentiation and mineralization of osteoblasts in mouse embryonic osteoblasts, enhances the alkaline phosphatase activity of osteoblasts, and alleviates the reduction of bone mineralization of zebrafish models induced by dexamethasone. New drug or food candidates for preventing and treating osteoporosis are provided.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118924776A_ABST
    Figure CN118924776A_ABST
Patent Text Reader

Abstract

The invention belongs to the field of biological medicine food, and relates to application of secoxyloganic acid found through osteogenic cell membrane chromatography in preparation of a product for promoting bone growth or treating bone diseases. The severed loganin acid found through osteogenic cell membrane chromatography belongs to a hydrophilic compound, can up-regulate a cannabinoid receptor 2 and has more suitable physical and chemical properties, and it is found for the first time that severed loganin acid acting protein is located on a cell membrane, and the severed loganin acid has the advantages that the severed loganin acid can be used as a novel severed loganin acid derivative, and the severed loganin acid derivative can be used as a novel severed loganin acid derivative. The traditional Chinese medicine composition has a certain effect on preventing or treating osteoporosis.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of biomedicine and food, and relates to an application of cleaved oxidized loganinic acid discovered by osteoblast membrane chromatography in the preparation of products for promoting bone growth or treating bone diseases. Background Art

[0002] Osteoporosis (OP) is a common systemic metabolic bone disease. Its main pathogenesis is the imbalance of bone reconstruction and destruction, which is responsible for the osteoblastic and osteoclastic abilities in the body. This is closely related to the bone formation ability of osteoblasts and the bone resorption ability of osteoclasts. About 30% of women and 20% of men over the age of 50 will suffer osteoporotic fractures. Osteoporosis has become a serious public health problem in my country.

[0003] Although there are many types of drugs for the treatment of osteoporosis, including nuclear factor κB receptor activator ligand inhibitors, sclerostin inhibitors, bisphosphonates, parathyroid hormone, selective estrogen receptor modulators, calcium agents, etc., the above chemical drugs have a wide range of adverse reactions. Therefore, the active ingredients in natural medicines are of great significance for the prevention and treatment of OP.

[0004] Cannabinoid receptor 2 (CB2) is a G protein-coupled receptor (GPCR). Preclinical data indicate that CB2 activation has applicability in autoimmune and inflammatory diseases, pain, neurodegeneration, and osteoporosis. Various pharmacopoeias for cannabinoid ligands have been published (the 2020 edition of the Chinese Pharmacopoeia stipulates that peucedanum praeruptosae, calculated on a dry basis, shall contain no less than 0.90% peucedanum argenteum A (C21H22O7) and no less than 0.24% peucedanum argenteum B (C24H26O7). Peucedanum argenteum B, a chemical drug, is a white crystal that is soluble in organic solvents such as methanol, DSMO, and ethyl acetate, but insoluble in water. It inhibits inflammation by acting on CB2 receptors and is used for expectoration and asthma), which has made considerable progress in understanding CB2 function and extensive preclinical evaluation. However, most CB2 ligands are highly lipophilic and therefore unsuitable for clinical application due to unfavorable physicochemical properties. (Whiting ZM, Yin J, de la Harpe SM, Vernall AJ, Grimsey NL. Developing the Cannabinoid Receptor 2 (CB2) pharmacopoeia: past, present, and future. Trends Pharmacol Sci. 2022 Sep; 43 (9): 754-771. doi: 10.1016 / j.tips.2022.06.010. Epub 2022 Jul 26. PMID: 35906103.). The cleaved oxidized loganin acid discovered by osteoblast membrane chromatography in the present application is a hydrophilic compound that can upregulate cannabinoid receptor 2 and has more suitable physicochemical properties.

[0005] Cell membrane chromatography screening technology uses the specific interaction between drugs and cell membrane proteins to quickly screen out the active ingredients in natural medicines that act on cell membrane proteins. Secologanoside is a new anti-osteoporosis active substance screened from Cornus officinalis extract using osteoblast membranes. Existing studies have shown that secologanoside has anti-inflammatory, antioxidant and anti-tumor activities, but there is no research on promoting bone growth and development and anti-osteoporosis. Summary of the invention

[0006] In view of the shortcomings of the prior art, the purpose of the present invention is to provide a new use of scissic acid, which acts on cell membrane proteins, and specifically relates to its use in the preparation of drugs and foods for promoting bone growth or treating bone diseases.

[0007] In order to achieve the above-mentioned purpose, the present invention adopts the following technical solutions:

[0008] The application of cleaved oxidized loganinic acid in the preparation of a product that promotes bone growth, wherein the structural formula of the cleaved oxidized loganinic acid is:

[0009]

[0010] The invention relates to an application of oxidized loganinic acid in the preparation of a product for alleviating and / or treating bone diseases, wherein the bone diseases are osteomalacia, rickets or osteoporosis.

[0011] The application of off-oxidized loganin in the preparation of products with good molecular docking binding activity with membrane protein cannabinoid receptor 2CNR2.

[0012] Application of sequestered oxidized loganine in preparing products for upregulating the expression level of periostin cannabinoid receptor 2CNR2.

[0013] Among them, the sequestered oxidized loganinic acid acts as a hydrophilic compound and binds to the membrane protein cannabinoid receptor 2. The product is a product for promoting bone growth, relieving and / or treating bone diseases.

[0014] Application of serotonin in the preparation of products that promote proliferation, differentiation and maturation of osteoblasts.

[0015] Use of sequestered loganinic acid in the preparation of products for enhancing the alkaline phosphatase activity, and / or calcification degree, and / or osteogenic differentiation of osteoblasts.

[0016] Application of oxyloganylic acid in the preparation of products that alleviate dexamethasone-induced reduction in zebrafish bone mineralization.

[0017] Preferably, the product comprises a medicine or a food.

[0018] Preferably, the dosage form of the drug includes any one of suspension, granules, capsules, powders, tablets, emulsions, solutions, pills, injections, suppositories, enemas, aerosols, patches or drops.

[0019] Preferably, the administration routes of the drug include oral administration, sublingual administration, rectal administration, skin mucosal administration, inhalation administration or injection administration.

[0020] Preferably, the food comprises a health product or a dietary supplement.

[0021] Preferably, the food comprises solid food, liquid food or semi-solid food.

[0022] Preferably, the promoting bone growth and / or alleviating and / or treating bone diseases comprises at least one of the following effects (1)-(4):

[0023] (1) Enhance the alkaline phosphatase activity, calcification, and / or osteogenic differentiation of osteoblasts;

[0024] (2) Alleviate the dexamethasone-induced decrease in bone mineralization in zebrafish;

[0025] (3) It has good molecular docking binding activity with the membrane protein cannabinoid receptor 2CNR2;

[0026] (4) Upregulate the expression level of periostin cannabinoid receptor 2CNR2.

[0027] The present invention first discovered that oxyloganine has certain effects on promoting bone growth and differentiation and preventing or treating bone diseases:

[0028] (1) The present invention found that oxyloganine has the effect of promoting proliferation, differentiation and maturation of osteoblasts, which is manifested in promoting cell proliferation, ALP activity and bone nodule mineralization of mouse embryonic osteoblast precursor cells MC3T3-E1, which is specifically manifested as follows:

[0029] In mouse embryonic osteoblast precursor cells MC3T3-E1, the cell proliferation rates of the low, medium and high dose groups were 1.21 times, 1.24 times and 1.26 times that of the blank control group, respectively; in the osteoblasts induced to differentiate from mouse embryonic osteoblast precursor cells MC3T3-E1, the relative ALP activities of the low, medium and high dose groups were 1.13 times, 1.16 times and 1.23 times that of the blank control group, respectively; the degree of bone nodule mineralization of the low, medium and high dose groups were 1.16 times, 1.95 times and 3.09 times that of the blank control group, respectively.

[0030] (2) The present invention found that oxyloganine can enhance the bone mineralization of zebrafish in the dexamethasone-induced osteoporosis model group and can fight osteoporosis in vivo, as shown in the following:

[0031] In the zebrafish of the dexamethasone-induced osteoporosis model group, the osteogenic fluorescence intensity increased in a dose-dependent manner. The osteogenic fluorescence intensity of the low-, medium-, and high-dose groups were 1.28 times, 1.48 times, and 1.72 times that of the model group, respectively.

[0032] (3) The present invention found that through molecular docking analysis, the results showed that the binding free energy of off-oxidized loganinic acid with CNR2 was -8.5 kcal / mol, and there were 12 hydrogen bonds between it and its amino acid residues, which showed good binding activity.

[0033] (4) The present invention found that the off-oxidized loganinic acid can up-regulate the expression of the membrane protein CNR2 in mouse embryonic osteoblast precursor cells MC3T3-E1, which is specifically manifested as follows:

[0034] In the osteoblasts induced and differentiated from mouse embryonic osteoblast precursor cells MC3T3-E1 cells, the expression levels of CNR2 in the low-, medium- and high-dose experimental groups increased by 1.06-, 1.36- and 1.57-fold, respectively, compared with the blank control group.

[0035] The cleaved oxidized loganinic acid found by osteoblast membrane chromatography in the present invention is a hydrophilic compound that can upregulate cannabinoid receptor 2 and has more suitable physical and chemical properties. It is the first time that the cleaved oxidized loganinic acid action protein is found to be located in the cell membrane, and has a certain effect on preventing or treating osteoporosis. The compound is obtained by screening from Cornus officinalis using osteoblast membrane proteins, and can (1) promote the proliferation of mouse embryonic osteoblast precursor cells MC3T3-E1, enhance the ALP activity of osteoblasts induced by MC3T3-E1 and the formation of mineralized bone nodules; (2) repair the reduced degree of bone mineralization in osteoporotic zebrafish induced by dexamethasone; (3) obtain osteoblast-related membrane protein CNR2 with good binding activity through molecular docking technology; (4) can upregulate the expression of osteoblast-related membrane protein CNR2. The present invention provides a new candidate for preparing a new drug or functional food for preventing and treating osteoporosis. The present invention provides a new candidate for preparing a new drug or functional food for preventing and treating osteoporosis. BRIEF DESCRIPTION OF THE DRAWINGS

[0036] Figure 1 The chemical structure diagram of secologanoside involved in the present invention.

[0037] Figure 2 This is a graph showing the cell proliferation results of MC3T3-E1 cells treated with low-dose, medium-dose and high-dose oxidized loganinic acid provided in Example 1 of the present invention.

[0038] Figure 3 This is a quantitative result diagram of ALP activity of MC3T3-E1 provided in Example 1 of the present invention after being induced to differentiate and treated with low-dose, medium-dose and high-dose interrupted oxidized loganinic acid.

[0039] Figure 4 This is a diagram showing the ALP staining results of MC3T3-E1 provided in Example 1 of the present invention after being induced to differentiate and treated with low-dose, medium-dose and high-dose interrupted oxidized loganinic acid.

[0040] Figure 5 This is a diagram showing the results of Alizarin Red staining of MC3T3-E1 provided in Example 1 of the present invention after induction of differentiation and treatment with low-dose, medium-dose and high-dose discontinuous oxidized loganinic acid.

[0041] Figure 6This is a semi-quantitative result diagram of Alizarin red staining of MC3T3-E1 provided in Example 1 of the present invention after induction of differentiation and treatment with low-dose, medium-dose and high-dose interrupted oxidized loganinic acid.

[0042] Figure 7 This is a graph showing the fluorescence intensity of osteogenesis in zebrafish of the dexamethasone-induced osteoporosis model provided in Example 2 of the present invention when the zebrafish were treated with low-dose, medium-dose and high-dose interrupted oxidized loganine.

[0043] Figure 8 This is a quantitative result diagram of the degree of bone mineralization in zebrafish of the dexamethasone-induced osteoporosis model provided in Example 2 of the present invention, which is treated with low-dose, medium-dose and high-dose interrupted oxidized loganine.

[0044] Fig. 9 It is a schematic diagram of the molecular docking results of off-oxidized loganinic acid and CNR2 provided in Example 3 of the present invention.

[0045] Fig.10 It is a statistical graph (CNR2) of the immunoblotting results of MC3T3-E1 provided in Example 4 of the present invention, which was treated with low-dose, medium-dose and high-dose oxidized loganinic acid after induction of differentiation. DETAILED DESCRIPTION

[0046] The technical scheme of the present invention is further described below by specific embodiments. It should be understood by those skilled in the art that the implementation cases are only to help understand the present invention and should not be regarded as specific limitations of the present invention. Unless otherwise specified, the reagents, methods and equipment used in the present invention are conventional reagents, methods and equipment in the art.

[0047] Example 1

[0048] Effects of secologanoside on the proliferation activity and osteogenic differentiation of mouse embryonic osteoblast precursor cells MC3T3-E1.

[0049] MC3T3-E1 was seeded in a 96-well plate at a seeding density of 2 × 10 4 The cells were cultured in a 37°C incubator with 5% CO2 for 24 hours to allow the cells to fully adhere to the wall. The cells were treated with the selected potential active ingredients of Cornus officinalis (segmented oxyloganine) at low, medium and high doses of 2.5nM, 5nM and 10nM for 48 hours, and the cell proliferation rate was detected using the CCK-8 kit.

[0050] Table 1 Cell proliferation experiment grouping

[0051]

[0052]

[0053] MC3T3-E1 was seeded in a 48-well plate at a seeding density of 5 × 10 4 cells. After the cells were fully attached, the cell culture medium was replaced with an osteogenic induction medium containing 50 μg / mL ascorbic acid, 10 μM dexamethasone, and 5 mM β-glycerophosphate sodium α-MEM complete medium to promote osteogenic differentiation. The cells were treated with different doses of oxidized loganine for 7 days, and the cell culture medium was renewed every 2 days. After the treatment time, the cells were lysed on ice for 30 minutes with Western and IP cell lysis buffer, and the ALP activity was detected according to the alkaline phosphatase detection kit.

[0054] Inoculate 2×10 4 The cells were placed in a 96-well plate and treated with the above steps. After the drug treatment time was reached, the staining reaction solution was prepared according to the BCIP / NBT alkaline phosphatase colorimetric kit, and the ALP staining image data was recorded using a microscope.

[0055] Inoculate 2×10 4 The cells were placed in a 96-well plate, and after they were completely attached, they were replaced with osteogenic induction solution and cultured for 14 days, followed by 7 days of treatment with oxyloganine. After the drug treatment time was reached, 50 μL of 4% paraformaldehyde was added to each well to fix the cell morphology for 10 minutes, rinsed twice with PBS, and added with alizarin red staining solution for 30 minutes. After staining, the excess staining solution was removed and rinsed twice with PBS, and after drying naturally at room temperature, the image data was recorded using a microscope. After the shooting was completed, the bone nodules were dissolved with 10% (w / v) sodium cetylpyridinium phosphate, and the absorbance was measured at 570nm for semi-quantitative detection.

[0056] Table 2 Grouping of cell differentiation and maturation experiments

[0057]

[0058] The cell proliferation rate results are as follows Figure 2 As shown, the three doses of serotoninic acid, low, medium and high, all promote the proliferation of MC3T3-E1 cells. The proliferation rates of MC3T3-E1 cells in the low, medium and high dose groups were 1.21 times (P < 0.001), 1.24 times (P < 0.001) and 1.26 times (P < 0.001) of those in the blank control group, respectively.

[0059] ALP activity results Figure 3-4As shown, in osteoblasts induced and differentiated from mouse embryonic osteoblast precursor cells MC3T3-E1, the relative activities of ALP in the low, medium and high dose groups were 1.13 times (P < 0.001), 1.16 times (P < 0.001) and 1.23 times (P < 0.001) of that in the blank control group, respectively.

[0060] The results of bone nodule mineralization are as follows Figure 5-6 As shown, in the osteoblasts differentiated by mouse embryonic osteoblast precursor cells MC3T3-E1, the mineralization degrees of bone nodules in the low, medium and high dose groups were 1.16 times (P < 0.001), 1.95 times (P < 0.001) and 3.09 times (P < 0.001) of that in the blank control group, respectively.

[0061] It can be seen that serotonin can significantly promote the proliferation of mouse embryonic osteoblast precursor cells MC3T3-E1 and promote their differentiation and maturation into osteoblasts.

[0062] Example 2

[0063] Anti-osteoporotic effect of secologanoside on dexamethasone-induced osteoporosis model zebrafish.

[0064] Zebrafish were raised in fish farming water at 28°C (water quality: 200 mg of instant sea salt was added to every 1L of reverse osmosis water, conductivity was 450-550 μS / cm; pH was 6.5-8.5; hardness was 50-100 mg / L CaCO3), the experimental animal use license number was SYXK (Zhejiang) 2022-0004, and the feeding and management complied with the international AAALAC certification (certification number: 001458), IACUC ethics review number: IACUC-2023-7682-01. Wild-type AB strain zebrafish 3 days after fertilization (3 dpf) were randomly selected and 30 were placed in each beaker. A blank control group and a model group were set up, the positive control (alendronate sodium) was administered 5.00 μg / mL, and the oxidized loganine was administered at 62.5, 125, and 250 μg / mL respectively using ultrapure water as a diluent. Except for the blank control group, all other groups were given dexamethasone to establish a zebrafish osteoporosis model. After 96 hours of administration at 28°C, the zebrafish were stained with alizarin red, and 8 zebrafish were randomly selected from each experimental group and photographed and preserved under a fluorescence microscope. The fluorescence intensity of the zebrafish spine was recorded and analyzed using NIS-Elements D3.20 advanced image processing software to evaluate the anti-osteoporosis effect.

[0065] Table 3 Zebrafish experimental grouping

[0066] Group Modeling Treatment Control group Without dexamethasone Normal feeding Model Group Give dexamethasone Normal feeding Positive drug group Give dexamethasone Normal feeding + positive control (alendronate sodium) 5.00 μg / mL administration for 96 hours Low dose group Give dexamethasone Normal feeding + 62.5μg / mL oxyloganine administration for 96h Medium dose group Give dexamethasone Normal feeding + 125 μg / mL oxyloganine administration for 96 hours High dose group Give dexamethasone Normal feeding + 250 μg / mL oxyloganine administration for 96 hours

[0067] Anti-osteoporosis effect of dexamethasone-induced osteoporosis zebrafish model Figure 7-8 As shown, the fluorescence intensity of osteogenic changes increased in a dose-dependent manner, and the fluorescence intensity of osteogenic changes in the low, medium and high dose groups were 1.28 times (P < 0.001), 1.48 times (P < 0.001) and 1.72 times (P < 0.001) of that in the model group, respectively. In vivo animal experiments have confirmed that oxyloganine has the effect of alleviating osteoporosis and can be used for the prevention and treatment of osteoporosis.

[0068] Example 3

[0069] Molecular docking mechanism of secologanoside and osteoporosis-related membrane proteins.

[0070] The 3D structure of cleaved oxidized loganinic acid (Mol2 format) was downloaded from the TCMSP database. The corresponding crystal structure of osteoporosis-related membrane proteins was downloaded from the PDB database, and corresponding treatments such as hydrogenation and dehydration were performed. The molecular docking analysis of small molecules and proteins was performed using AutoDock vina software, and the docking result scores are shown in Table 4. Among them, the docking score of cleaved oxidized loganinic acid and CNR2 is the lowest, indicating that the possibility of binding between the two is the greatest and the binding product of the two is the most stable. The docking results were visualized using Pymol. Fig. 9 It can be seen that broken-oxidized loganinic acid can form hydrogen bonds with amino acid residues ARG-150, THR-102, CYS-103 3.4, ASN-230, HIS-213, MET-61 and LEU-318 in CNR2. Broken-oxidized loganinic acid has good binding activity with membrane protein CNR2 and may be the membrane protein it acts on.

[0071] Table 4 Docking results of oxyloganylic acid and osteoporosis-related membrane protein molecules

[0072]

[0073]

[0074] Example 4

[0075] Effect of secologanoside on the expression level of osteogenesis-related membrane proteins.

[0076] MC3T3-E1 was seeded in a 6-well plate at a seeding density of 1×10 5cells, cell culture conditions and administration methods are the same as those described in "Example 1". After administration, 150 μL of a mixture containing Western and IP cell lysates, protease inhibitors, phosphoproteinase inhibitors, and PMSF (950:20:20:10) was added to each well, incubated on ice for 20 minutes, and then placed in a low-temperature high-speed centrifuge for centrifugal precipitation. Centrifuge operating parameters: centrifuge at 12000 rpm for 20 minutes at 4°C. The supernatant was subjected to protein quantitative detection. After the protein amount was unified by the BCA kit, 5×SDS-PAGE protein loading buffer (4:1) was added according to the actual volume of the supernatant, heated in a 100°C metal bath for 10 minutes, and stored at -20°C.

[0077] Prepare 10% SDS-PAGE gel, and after loading, electrophoresis was performed at 80V constant voltage for 30 minutes, and then the voltage was increased to 120V constant voltage electrophoresis until the sample reached the bottom of the gel. Polyvinylidene fluoride (PVDF) blotting membrane can be used after being activated by anhydrous ethanol for 5 minutes. Prepare pre-cooled transfer solution and transfer the membrane at 250mA constant current for 120 minutes. Soak the PVDF membrane after transfer in 5% bovine serum albumin solution and incubate on a shaker at room temperature for 2 hours. The PVDF membrane was incubated with antibody protein CNR2 (1:3000) and internal reference GAPDH (1:3000) at 4°C overnight. The next day, the secondary antibody was labeled with HRP horseradish peroxidase (1:2000) and incubated on a shaker at room temperature for 1 hour. Each time the incubation solution was changed, the PVDF membrane was washed 3 times with TBST at room temperature for 10 minutes each time. Finally, the PVDF membrane was developed by chemiluminescence and the grayscale value was analyzed using Image J software.

[0078] The results of the effect of oxidized loganine on the expression level of CNR2 are as follows Fig.10 As shown, the expression levels of CNR2 in the low-, medium- and high-dose experimental groups were increased by 1.06-, 1.36-, and 1.57-fold (P < 0.001), respectively, compared with the blank control group.

[0079] The applicant declares that the present invention uses the above-mentioned embodiments to illustrate the application of the oxyloganylic acid of the present invention in the preparation of anti-osteoporosis drugs or functional foods, but the present invention is not limited to the above-mentioned embodiments, that is, it does not mean that the present invention must rely on the above-mentioned embodiments to be implemented. Those skilled in the art should understand that any improvement of the present invention, equivalent replacement of various raw materials of the product of the present invention, etc., all fall within the protection scope and disclosure scope of the present invention.

[0080] The preferred embodiments of the present invention are described in detail above. However, the present invention is not limited to the specific details in the above embodiments. Within the technical concept of the present invention, a variety of simple modifications can be made to the technical solution of the present invention, and these simple modifications all belong to the protection scope of the present invention.

[0081] It should also be noted that in the above specific implementation modes, the various specific technical features described can be combined in any suitable manner without contradiction. In order to avoid unnecessary repetition, the present invention will not separately describe various possible combinations.

[0082] Although the present invention has been disclosed as above in the form of a preferred embodiment, it is not intended to limit the present invention. Anyone familiar with this technology can make various changes and modifications without departing from the spirit and scope of the present invention. Therefore, the scope of protection of the present invention should be based on the definition of the claims.

Claims

1. Use of cleaved oxidized loganinic acid in the preparation of products for promoting bone growth, alleviating and / or treating bone diseases, wherein the structural formula of the cleaved oxidized loganinic acid is:

2. The application of off-oxidized loganine in the preparation of products with good molecular docking binding activity with membrane protein cannabinoid receptor 2.

3. Use of sequestered strychnine in the preparation of products for upregulating the expression level of periostin cannabinoid receptor 2.

4. The use according to claim 3 or 4, characterized in that: Sequential oxylognylic acid binds to cannabinoid receptor 2 as a hydrophilic compound.

5. The use according to claim 1, 3 or 4, characterized in that: The product is a product for promoting bone growth, alleviating and / or treating bone diseases.

6. The use according to claim 5, characterized in that: The bone disease is osteomalacia, rickets or osteoporosis.

7. The use according to claim 1, 3 or 4, characterized in that: Application of serotonin in the preparation of products that promote proliferation, differentiation and maturation of osteoblasts.

8. The use according to claim 6, characterized in that: Sterilization of loganine enhances the alkaline phosphatase activity, and / or calcification, and / or osteogenic differentiation of osteoblasts.

9. The application of serotonin in the preparation of products to alleviate the dexamethasone-induced decrease in zebrafish bone mineralization.

10. The use according to claim 1, 3 or 4, characterized in that: The product is a medicine or food; the dosage form of the medicine includes any one of suspension, granules, capsules, powders, tablets, emulsions, solutions, pills, injections, suppositories, enemas, aerosols, patches or drops; the food includes solid food, liquid food or semi-solid food.